Please login to the form below

Bluebird Bio

This page shows the latest Bluebird Bio news and features for those working in and with pharma, biotech and healthcare.

Europe responding to gene therapy challenge, but picture remains fragmented

Also addressing the conference separately was Doug Denison, head of global pricing and reimbursement at Bluebird Bio, who was explaining the company's payment by instalment system it is proposing for

Latest news

Bluebird and Alexion veterans launch cell and gene venture ElevateBio

Massachusetts. The company was unveiled yesterday by its co-founders David Hallal and Vikas Sinha, previously last chief exec and chief financial officer respectively of Alexion, with ex-Bluebird Bio chief
Bluebird’s myeloma CAR-T safety ‘could support outpatient use’

Expects to file with the FDA next year. Bluebird Bio and partner Celgene have published data for their BCMA-targeting cell therapy bb2121 for multiple myeloma, reinforcing its position as the ... bb2121 is now in a pivotal phase 2 trial – called KarMMA
Orphan drugs market to soar to $224bn by 2024

Cell and gene therapies to fuel growth. Breakthrough “one and done” treatments such as Novartis’ Zolgensma and bluebird bio’s Lentiglobin will contribute to a 12% compound annual growth rate (CAGR)
Poseida gets Novartis backing for myleoma CAR-T challenger

There are a number of companies already pursuing this pathway, most notably Bluebird Bio and Celgene, whose bb2121 is currently in pole position in the BCMA-targeting class, and looks set
Janssen’s CAR-T gains PRIME status in Europe

Bluebird Bio and Celgene and currently seen as the frontrunners with their late-stage CAR-T candidate bb21217, while Celgene has a similar challenger in development with Juno.

More from news
Approximately 8 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

LentiGlobin (betibeglogene darolentivec), an Orphan Drug and Breakthrough Therapy from Bluebird Bio, corrects the defect causing beta thalassemia, a blood disorder that causes life-threatening anaemia.
Drug launches to watch in 2019

7. LentiGlobin TDT – a gene therapy first for Europe. Gene therapy company Bluebird Bio is on course to gain approval for its first product this year – and Europe is expected to ... Bluebird says its decision to file in Europe first was in part
Regeneron and Bluebird sign $100m cell therapies deal

Six targets chosen from TCR and other cell therapy platforms. ‘Big biotech’ Regeneron and cell and gene therapy specialists Bluebird Bio have unveiled a new collaboration which gives both greater presence ... The collaboration with Regeneron
Bluebird Bio: on the cusp of a gene therapy revolution

Bluebird Bio's chief executive Nick Leschly. Cell and gene therapy made the transition from an interesting but unproven science to medical reality in 2017, with two ‘living medicine’ CAR-T ... The next company to play its hand in this biotech-led
Deal Watch September 2016

The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 1, 695. Medigene /Bluebird bio. Licence. Development and

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

Proteostasis Therapeutics strengthens leadership team

James DeTore (pictured) becomes the biopharmaceutical firm's chief financial officer, bringing experience from bluebird bio, Ironwood Pharmaceuticals and Microbia.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Midweight Brand Planner: Up to £50, 000

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Head of Partnerships - Competitive - London: Competitive Salary Offered

Senior / Principal Medical Writer / ETL - MedComms - HOME BASED ...: D.O.E

Subscribe to our email news alerts

PMHub

Add my company

M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

The Exhibition Hall: Past, Present and Future: As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success: This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change: ...